Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation

A Correction to this article was published on 23 July 2020

This article has been updated


A systematic review of pharmacogenomic studies capturing adverse drug reactions (ADRs) related to asthma medications was undertaken, and a survey of Pharmacogenomics in Childhood Asthma (PiCA) consortia members was conducted. Studies were eligible if genetic polymorphisms were compared with suspected ADR(s) in a patient with asthma, as either a primary or secondary outcome. Five studies met the inclusion criteria. The ADRs and polymorphisms identified were change in lung function tests (rs1042713), adrenal suppression (rs591118), and decreased bone mineral density (rs6461639) and accretion (rs9896933, rs2074439). Two of these polymorphisms were replicated within the paper, but none had external replication. Priorities from PiCA consortia members (representing 15 institution in eight countries) for future studies were tachycardia (SABA/LABA), adrenal suppression/crisis and growth suppression (corticosteroids), sleep/behaviour disturbances (leukotriene receptor antagonists), and nausea and vomiting (theophylline). Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy.


Asthma is a common chronic condition, affecting over 230 million people worldwide [1,2,3]. The management of asthma is guided by national and international evidence based guidelines [4, 5], but there is inter-individual variability in treatment response. This variation may be related to several factors, including adherence, disease subtype and severity, and environmental factors. In addition, a patient’s genotype can affect outcomes of treatment in asthma [6,7,8]. The data from these pharmacogenomic studies of asthma medication efficacy in children have progressed to the point where there are now polymorphisms approaching clinical utility [9].

However, the overall effectiveness of a medicine is a balance between the intended benefits and potential risks. Adverse drug reactions (ADRs) in asthma patients also need to be considered. The medications used in asthma have a well described set of ADRs associated with their use (Table 1). In adult patients, ADRs are responsible for 6.5% of all admissions, while 14.7% of adult inpatients experience an ADR [10, 11]. For paediatrics, 3% of all admissions are related to ADRs [12], while over 17% of all paediatric inpatients experience one or more ADR [13]. For asthmatic patients, ADRs represent a significant burden, reducing their quality of life, and extract an economic cost on healthcare systems worldwide [14, 15].

Table 1 List of adverse drug reactions for asthma drug classes (adapted from BNFC [24]).

There is inter-individual variability in the type and severity of ADR experienced by patients. Factors such as adherence, and disease subtype influence this, but genomic factors are also important [16], with several genetic polymorphisms having been associated with severe ADRs [17, 18]. Regulatory information to guide prescribers has been updated to reflect these findings [19].

While the effect size in pharmacogenomic studies is often larger than that seen in genetic epidemiology studies [20], large cohorts are still required, and replication of findings is essential if findings are to be adopted into clinical practice [21]. International consortia, utilising the data from multiple groups, have been developed to facilitate this process [22]. Within asthma, the pharmacogenomics in childhood asthma (PiCA) consortia is well established, containing multiple cohorts from studies around the world [23].

Our aim was to undertake a systematic review of pharmacogenomic studies of ADRs related to asthma medications across the entire population. In addition, in collaboration with the PiCA consortia, a survey of research active groups in this area was undertaken to establish the current prioritisation of ADRs within asthma pharmacogenomic research, and to determine the future research priorities.


A systematic review of current evidence investigating ADRs of asthma medications in pharmacogenomic studies was undertaken. A protocol was submitted to the PICA consortia before commencing.


Electronic databases, Medline, Embase, and CINAHL, were searched up till January 2018 to locate eligible studies, using the terms “asthma” AND “pharmacogenomics” AND “asthma medication”. A list of asthma medication for inclusion in the search strategy was extracted from the British National Formulary for Children (BNFC) with both generic and brand names included (see Supplementary file for full search strategy). No limit was placed on language, publication date, or age of study population. References of included studies were analysed to locate any additional relevant studies of interest.

Study selection

Two reviewers (CK and DH), after removal of duplicates, independently screened titles and abstracts for inclusion, analysed full text for eligibility, and collectively completed data extraction. Disagreements between the two reviewers were discussed and resolved mutually.

Both randomised control trials (RCTs) and observational studies were included. Studies were deemed eligible if genome analysis had been undertaken, the researchers examined a known drug used in asthma treatment and if ADRs were stated. ADRs were included if stated as either a primary or a secondary outcome of the study. An ADR was classified according to the WHO definition [24]. A list of the top ADRs for each class of asthma medication is shown in Table 1 [25, 26]. Studies had to state the specific ADRs related to asthma medications and were excluded if ADRs were stated to be seen but no report produced with data. An asthma exacerbation was classified as a failure of medication efficacy rather than an ADR.

Quality assessment and analysis

Methodological quality assessment was undertaken of the included studies: the Newcastle–Ottawa Quality Assessment Scale [27] was used for cohort and case–control studies, and the Cochrane Risk of Bias tool for RCTs [28].

Results were extrapolated into a pre-determined data table, and a qualitative analysis then conducted on the extracted data, with each asthma medication then individually reported.

PiCA survey

An online survey was undertaken of PiCA consortia members to establish if this review had identified all possible pharmacogenomic studies analysing ADRs and asthma. In addition, the survey collated responses regarding the importance of capturing ADRs in future studies, and which ADRs’ members felt should be investigated in the future.

Fig. 1

Prisma flowchart showing screening and inclusion of studies.


There were 1409 results after removal of duplicates generated from the search strategy, but of these, only five were eligible for inclusion [29,30,31]. From the survey sent, two additional studies were discovered [32, 33] (Fig. 1). Adverse events such as decreased efficacy or increased asthma exacerbations were reported in some papers, but as pre-specified, these were not included. Within the eligible studies, a three reported on ADR’s as an end point of their studies.

In the included studies, four were RCTs [29, 30, 32, 33], and one was a cohort study [31]. All included studies had a low risk of bias (see Supplementary file). Two of the studies were undertaken in the United Kingdom with the other three having been carried out in the USA. The overall sample size of the studies was 1457 participants, with the largest proportion of participants being from a paediatric population. The characteristics of the included studies are shown in Table 2.

Table 2 Characteristics of included studies.

One study examined ADRs with inhaled short acting beta-2 agonists (SABA) [29], one analysed long acting beta-2 agonists (LABA) [30], three studies examined the use of corticosteroids [31,32,33], while no studies have examined ADRs occurring with either leukotriene receptor antagonists (LTA) or theophylline. For the SABA and LABA studies, a candidate gene approach was applied [29, 30], whereas in the three corticosteroid studies, genome-wide association studies (GWAS) were used [31,32,33].

When analysing the genes identified in the studies, the candidate gene studies examined the SNP rs1042713, on the beta-2 adrenergic receptor gene (ADRB2). In contrast, the platelet derived growth gene (PDGFD), the rap guanine nucleotide exchange factor 5 gene (RAPGEF5), the tubulin folding cofactor D (TBCD), and the tubulin gamma 1 gene (TUBG1) were all identified through GWAS. The ADR’s associated with each SNP, and presence or absence of replication datasets, is shown in Table 3.

Table 3 Adverse drug reaction for each SNP in included studies.

Regarding the ADR’s in SABAs, one study [29], examining 78 adults found that if participants had the homozygous Arg16/Arg16 allele then the performance was lower when on albuterol compared with the placebo, with the peak expiratory flow rate being 23 L/min better when albuterol was stopped. However, when this was replaced with ipratropium bromide, an anti-muscarinic, this group of participants had higher peak flow rates than when on albuterol or placebo.

For LABAs, one study [30] that had examined 22 adult participants found that participants with the homozygous Gly16/Gly16 genotypes had maximum FEV1, maximum FEF25–75, 6 h FEV1, and 6 h FEF25–75 values lower compared with the Arg16/Arg16 genotype when given formoterol.

With inhaled corticosteroids, one study [31], examining 407 children from the PASS (Pharmacogenetics of Adrenal Suppression with Inhaled Steroids) study aged 5–18 years found that the SNP rs591118, located in the vicinity of the PDGFD gene, was associated with a higher risk of adrenal suppression (odds ratio in the paediatric asthma replication cohort 3.86, 95% CI 1.19–12.50).

For oral corticosteroids, two studies [32, 33] examined children aged 5–12 years, from the CAMP (Childhood Asthma Management Program) trial, and the effect of prednisone on bone mineral density (BMD) z scores and bone mineral accretion (BMA). For decreases in BMD-z scores one SNP was identified, rs6461639, and in the acute lymphoblastic leukaemia (ALL) replication cohort it was significant (p value = 0.016) [33]. With the other study [32], two associated SNPs were found to worsen BMA with increased prednisone dosage, rs989633 and rs207439.

Internal replication was undertaken in two of the studies, both that examined corticosteroids [31, 33]. However, additional publications attempting external replication of these polymorphisms have not been identified.

Survey results

There were 20 PiCA members who participated in the survey, representing 15 institutes from the consortia in 67% of participating countries. Ninety five percent identified ADRs as an area that should be captured in pharmacogenomic studies, and 80% of respondents agreed that only a small percentage of studies currently assessed this area. The survey respondents undertook a prioritisation exercise to establish the ADRs for each asthma medication they believe should be subject to further pharmacogenomics research. The results of this prioritisation exercise are shown in Table 4 (ranked in order of highest priority to lowest). The most important ADRs by consensus for each drug class varied; for beta-2 agonists (SABA or LABA) it was tachycardia, for corticosteroids it was both adrenal suppression/crisis and reduced growth, for LTAs it was sleep/behaviour disturbances, and for theophylline it was nausea and vomiting. Not all participants completed the survey for ADRs of each drug. For theophylline, 39% reported that the drug was no longer used in current treatment steps.

Table 4 ADR's from survey and number of people who prioritised each.


This is the first systematic review that considers the harms of anti-asthma medications and their relationship to an individual’s genetic variability. This systematic review has identified six different ADRs that have pharmacogenomic associations, but these are a small subset of the overall pharmacogenomic research in asthma. In addition, there is a lack of replication cohorts within the current evidence with only two studies including internal replication cohorts in their research. In both studies, these replication cohorts successfully demonstrated the associations with individual polymorphisms identified in the discovery cohort.

The survey of PiCA consortia members supported future pharmacogenomic research into ADRs in asthma, and prioritised ADRs for each anti-asthma medication class. For most of the prioritised ADRs, we have not been able to identify any published pharmacogenomic data. In addition, we note that while ADRs associated SABA/LABA medications were not the ones prioritised in the survey. However, for corticosteroids the ADRs identified in publications did correlate well with the ADRs prioritised in the survey. Asthma is a disease that is particularly suitable for personalisation of therapy to either select efficacious medicines or avoid harms, as there are several possible medications, and so alternate drug selections are possible.

A minority of participants in the survey commented about whether frequency of asthma exacerbations is an ADR for beta-2 agonists, corticosteroids, and LTA’s. They are included in the results of the survey. The protocol for the systematic review excluded these a priori as they were considered a failure of treatment, not a worsening of disease. However, we note the core outcome set for childhood asthma does include risk of hospitalisation secondary to asthma exacerbations. Reviewing the literature, asthma exacerbations have been defined as adverse events rather than ADRs in previous pharmacogenomic studies [6, 34, 35]. A study, examining children with asthma who were on ICS plus LABA identified an increase of asthma exacerbations of 52% in those homozygous for the Arg16/Arg16 allele of ADRB2 [34]. However, it needs to be determined if asthma exacerbations should be classified as an ADR in future studies or is to do with efficacy instead. Desensitisation to these medications may also occur. This was considered for the included studies examining lung function, but they were included as either the lung function was worse than placebo [29] or there was no placebo to compare against [30].

A limitation of this study is that, as for any systematic review, the quality of the data produced is dependent on the quality of existing publications, and there were a paucity of eligible papers covering a range of drugs and ADRs. These studies all had relatively small sample sizes, and the diversity of ADRs identified precluded meta-analysis. However, the identification and prioritisation of ADRs by members of the PiCA consortia is a positive indicator that future pharmacogenomic studies may include more ADRs as well as markers of efficacy.


There are few pharmacogenomic studies of ADRs in asthma that have been undertaken. None of the studies that have been undertaken have been externally replicated, although one has only just been published. Future pharmacogenomic studies in asthma should collect relevant ADR data as well as markers of efficacy. Drug specific ADR priorities have been established to guide researchers.

Change history

  • 23 July 2020

    The original version of this Article did not include Juan C. Celedón, Erick Forno and Glorisa Canino in the list of authors and incorrectly cited Gerard H. Koppelman, Maria Pino-Yanes and Steve Turner as authors. This has now been corrected in both the PDF and HTML versions of the Article.

  • 08 February 2021

    A Correction to this paper has been published:


  1. 1.

    Deen JL, Vos T, Huttly SR, Tulloch J. Injuries and noncommunicable diseases: emerging health problems of children in developing countries. Bull World Health Organ. 1999;77:518–24.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Global Asthma Network. The global asthma report 2014. Auckland, New Zealand: Global Asthma Network; 2014. 769.

  3. 3.

    World Health Organization. Asthma fact sheet no. 307. 2013. http://www.whoint/topics/asthma/es 2016.

  4. 4.

    Society BT. British guideline on the management of asthma. Thorax. 2014;69:i1–i192.

    Google Scholar 

  5. 5.

    Reddel HK, Bateman ED, Becker A, Boulet L-P, Cruz AA, Drazen JM, et al. A summary of the new GINA strategy: a roadmap to asthma control. Eur Respiratory J. 2015;46:622–39.

    CAS  Article  Google Scholar 

  6. 6.

    Basu K, Palmer CN, Tavendale R, Lipworth BJ, Mukhopadhyay S. Adrenergic beta(2)-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol. J Allergy Clin Immunol. 2009;124:1188–1194.e1183.

    CAS  Article  Google Scholar 

  7. 7.

    Palmer CN, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax. 2006;61:940–4.

    CAS  Article  Google Scholar 

  8. 8.

    Zuurhout MJ, Vijverberg SJ, Raaijmakers JA, Koenderman L, Postma DS, Koppelman GH, et al. Arg16 ADRB2 genotype increases the risk of asthma exacerbation in children with a reported use of long-acting beta2-agonists: results of the PACMAN cohort. Pharmacogenomics. 2013;14:1965–71.

    CAS  Article  Google Scholar 

  9. 9.

    Farzan N, Vijverberg SJ, Kabesch M, Sterk PJ, Maitland‐van der Zee AH. The use of pharmacogenomics, epigenomics, and transcriptomics to improve childhood asthma management: where do we stand? Pediatr Pulmonol. 2018;53:836–45.

    Article  Google Scholar 

  10. 10.

    Davies EC. Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. PLoS One. 2009;4:e4439.

    Article  Google Scholar 

  11. 11.

    Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004;329:15–19.

    Article  Google Scholar 

  12. 12.

    Gallagher RM, Mason JR, Bird KA, Kirkham JJ, Peak M, Williamson PR, et al. Adverse drug reactions causing admission to a paediatric hospital. PLoS One. 2012;7:e50127.

    CAS  Article  Google Scholar 

  13. 13.

    Thiesen S, Conroy EJ, Bellis JR, Bracken LE, Mannix HL, Bird KA, et al. Incidence, characteristics and risk factors of adverse drug reactions in hospitalized children—a prospective observational cohort study of 6,601 admissions. BMC Med. 2013;11:237.

    Article  Google Scholar 

  14. 14.

    Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469–78.

    Article  Google Scholar 

  15. 15.

    Gergen PJ. Understanding the economic burden of asthma. J Allergy Clin Immunol. 2001;107:S445–448.

    CAS  Article  Google Scholar 

  16. 16.

    Wei C-Y, Michael Lee M-T, Chen Y-T. Pharmacogenomics of adverse drug reactions: implementing personalized medicine. Hum Mol Genet. 2012;21:R58–R65.

    CAS  Article  Google Scholar 

  17. 17.

    Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486.

    CAS  Article  Google Scholar 

  18. 18.

    Nguyen CM, Mendes MA, Ma JD. Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression risk. PLoS Curr. 2011;3:RRN1236.

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Ferrell PB, McLeod HL. Carbamazepine, HLA-B* 1502 and risk of Stevens–Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics. 2008;9:1543–6.

  20. 20.

    Maranville JC, Cox NJ. Pharmacogenomic variants have larger effect sizes than genetic variants associated with other dichotomous complex traits. Pharmacogenom J. 2016;16:388.

    CAS  Article  Google Scholar 

  21. 21.

    Chanock SJ, Manolio T, Boehnke M, Boerwinkle E, Hunter DJ, Thomas G, et al. Replicating genotype–phenotype associations. Nature. 2007;447:655.

    CAS  Article  Google Scholar 

  22. 22.

    Motsinger-Reif AA, Jorgenson E, Relling MV, Kroetz DL, Weinshilboum R, Cox NJ, et al. Genome-wide association studies in pharmacogenomics: successes and lessons. Pharmacogenet Genom. 2013;23:383.

    CAS  Article  Google Scholar 

  23. 23.

    Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, et al. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. Pharmacogenomics. 2017;18:931–43.

    CAS  Article  Google Scholar 

  24. 24.

    World Health Organization. International drug monitoring: the role of national centres, report of a WHO meeting [held in Geneva from 20 to 25 September 1971]. World Health Organization; 1972.

  25. 25.

    Leung JS, Johnson DW, Sperou AJ, Crotts J, Saude E, Hartling L, et al. A systematic review of adverse drug events associated with administration of common asthma medications in children. PLoS One. 2017;12:e0182738.

    Article  Google Scholar 

  26. 26.

    Paediatric Formulary Committee. BNF for Children (online). BMJ Group, Pharmaceutical Press and RCPCH publications: London; 2017. p Asthma.

  27. 27.

    Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. Newcastle-Ottawa quality assessment scale cohort studies. 2014.

  28. 28.

    Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.

    Article  Google Scholar 

  29. 29.

    Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505–12.

    CAS  Article  Google Scholar 

  30. 30.

    Tan S, Hall IP, Dewar J, Dow E, Lipworth B. Association between beta 2-adrenoceptor polymorphism and susceptibility to bronchodilator desensitisation in moderately severe stable asthmatics. Lancet. 1997;350:995–9.

    CAS  Article  Google Scholar 

  31. 31.

    Hawcutt DB, Francis B, Carr DF, Jorgensen AL, Yin P, Wallin N, et al. Susceptibility to corticosteroid-induced adrenal suppression: a genome-wide association study. Lancet Respir Med. 2018;6:442–50.

  32. 32.

    Park HW, Ge B, Tse S, Grundberg E, Pastinen T, Kelly HW, et al. Genetic risk factors for decreased bone mineral accretion in children with asthma receiving multiple oral corticosteroid bursts. J Allergy Clin Immunol. 2015;136:1240–6.

    CAS  Article  Google Scholar 

  33. 33.

    Park HW, Tse S, Yang W, Kelly HW, Kaste SC, Pui CH, et al. A genetic factor associated with low final bone mineral density in children after a long-term glucocorticoids treatment. Pharmacogenom J. 2017;17:180–5.

    CAS  Article  Google Scholar 

  34. 34.

    Turner S, Francis B, Vijverberg S, Pino-Yanes M, Maitland-van der Zee AH, Basu K, et al. Childhood asthma exacerbations and the Arg16 β2-receptor polymorphism: a meta-analysis stratified by treatment. J Allergy Clin Immunol. 2016;138:107–113. e105.

    CAS  Article  Google Scholar 

  35. 35.

    Koster E, Maitland‐van der Zee AH, Tavendale R, Mukhopadhyay S, Vijverberg S, Raaijmakers J, et al. FCER2 T2206C variant associated with chronic symptoms and exacerbations in steroid‐treated asthmatic children. Allergy. 2011;66:1546–52.

    CAS  Article  Google Scholar 

Download references


We would like to thank the NIHR Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC) for funding Amanda McKenna’s internship, and Charlotte Kings MPhil, and the members of the PiCA consortia for their help in completing the survey. U. Potočnik, K. Repnik and V. Berce were supported by SysPharmPedia grant, co-financed by Ministry of Education, Science and Sport of the Republic of Slovenia

Author information



Corresponding author

Correspondence to Daniel B. Hawcutt.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

King, C., McKenna, A., Farzan, N. et al. Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritisation. Pharmacogenomics J 20, 621–628 (2020).

Download citation

Further reading


Quick links